Opposite effects of midazolam and β-carboline-3-carboxylate ethyl ester on the release of dopamine from rat nucleus accumbens measured by in vivo mudialysis

European Journal of Pharmacology

Volumn 261, Issue 1-2, 1994, Pages 65-71

  Murai, Tameatsu ^a   Koshikawa, Noriaki ^a   Kanayama, Toshiyoshi ^a   Takada, Koji ^a   Tomiyama, Katsunori ^a   Kobayashi, Masafami ^a  

^a NIHON UNIVERSITY   (Japan)

Author keywords

Adenosine receptor; Dopamine release; GABAA benzodiazepine receptor; Midazolam; Nucleus accumbens; CCE ( carboline 3 carboxylate ethyl ester)

Indexed keywords

3,7 DIMETHYL 1 PROPARGYLXANTHINE; 4 AMINOBUTYRIC ACID A RECEPTOR; 8 CYCLOPENTYL 1,3 DIPROPYLXANTHINE; ADENOSINE A1 RECEPTOR; ADENOSINE A1 RECEPTOR AGONIST; ADENOSINE A1 RECEPTOR ANTAGONIST; ADENOSINE A2 RECEPTOR; ADENOSINE A2 RECEPTOR ANTAGONIST; BENZODIAZEPINE RECEPTOR; BETA CARBOLINE 3 CARBOXYLIC ACID ETHYL ESTER; CYCLOHEXYLADENOSINE; DOPAMINE; FLUMAZENIL; MIDAZOLAM; MIDAZOLAM MALEATE;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DOPAMINE RELEASE; DRUG ANTAGONISM; DRUG MECHANISM; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HISTOLOGY; INTRAPERITONEAL DRUG ADMINISTRATION; INTRAVENOUS DRUG ADMINISTRATION; MALE; NONHUMAN; NUCLEUS ACCUMBENS; PRIORITY JOURNAL; RAT;

ADENOSINE; ANIMAL; CARBOLINES; DOPAMINE; DOSE-RESPONSE RELATIONSHIP, DRUG; FLUMAZENIL; LIGANDS; MALE; MICRODIALYSIS; MIDAZOLAM; NUCLEUS ACCUMBENS; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, GABA-A; RECEPTORS, PURINERGIC P1; SUPPORT, NON-U.S. GOV'T; TETRODOTOXIN; THEOBROMINE; XANTHINES;

EID: 0028016184     PISSN: 00142999     EISSN: None     Source Type: Journal    
DOI: 10.1016/0014-2999(94)90301-8     Document Type: Article

References (43)

1. Differential effect of stress on in vivo dopamine release in striatum, nucleus accumbens and medial frontal cortex
2. 3H]-adenosine by rat cerebral cortical synaptosomes
3. mudialysis - theory and application
4. Determination of brain interstitial concentration by mudialysis
5. The anxiogenic β-carboline FG 7142 selectively increases dopamine release in rat prefrontal cortex as measured by mudialysis
6. Dopamine in the basal ganglia and benzodiazepine-induced sedation
7. Beta-carbolines enhance shock-induced suppression of drinking in rats
8. Tail-pinch stress increases extracellular DOPAC levels (as measured by in vivo voltammetry) in rat nucleus accumbens but not frontal cortex: antagonism by diazepam and zolpidem
9. Stress-induced increase in 3,4-dihydroxyphenyl-acetic acid (DOPAC) levels in the cerebral cortex and in nucleus accumbens: reversal by diazepam
10. The anxiogenic action of benzodiazepine antagonists
11. Benzodiazepine-induced decreases in extracellular concentrations of dopamine in the nucleus accumbens after acute and repeated administration
12. A receptor antagonists on extracellular dopamine levels
13. Chronic administration of diazepam downregulates adenosine receptors in the rat brain
14. Release of dopamine is reduced by diazepam more in the nucleus accumbens that in the caudate nucleus of conscious rats
15. The anxiogenic β-carboline FG-7142 increases in vivo and in vivo tyrosine hydroxylation in the prefrontal cortex
16. Intracerebral mudialysis. I. Experimental studies of diffusion kinetics
17. Anxiogenic drugs beta-CCE and FG 7142 increase extracellular dopamine levels in nucleus accumbens
18. Benzodiazepine inhibition of adenosine uptake is not prevented by benzodiazepine antagonists
19. Inhibition of adenosine accumulation by a CNS benzodiazepine antagonist (Ro 15-1788) and a peripheral benzodiazepine receptor ligandd (Ro 05-4864)
20. Intrinsic and antagonistic effects of beta-carboline FG-7142 on behavioral and EEG actions of benzodiazepines and pentobarbital in cats
21. Proconflict effect of benzodiazepine inverse agonists and other inhibitors of GABA function
22. Benzodiazepine interaction with adenosine systems explains some anomalies in GABA hypothesis
23. Inhibition of adenosine uptake into rat brain synaptosomes by prostaglandins, benzodiazepines and other centrally active compounds
24. Differential modulation of striatal dopamine release by intranigral injection of gamma-aminobutyric acid (GABA), dynorphin A and substance P
25. Striatonigral GABA, dynorphin, substance P and neurokinin A modulation of nigrostriatal dopamine release: evidence for direct regulatory mechanisms
26. Chronic caffeine or theophylline exposure reduces γ-aminobutyric acid/benzodiazepine receptor site interactions
27. The role of GABA receptors in the control of nigrostriatal dopaminergic neurons: dual probe mudialysis study in awake rats
28. An in Vivo Voltammetric Study of the Response of Mesocortical and Mesoaccumbens Dopaminergic Neurons to Environmental Stimuli in Strains of Rats with Differing Levels of Emotionality
29. 3.7-Dimethyl-1-propargylxanthine: a potent and selective in vivo antagonist of adenosine analogues
30. Intranigral GABAergic drugs effects on striatal dopamine activity
31. Discriminative and aversive properties of beta-carboline-3-carboxylic acid ethyl ester, a benzodiazepine receptor inverse agonist, in rhesus monkeys
32. Effects of midazolam and flunitrazepam on the release of dopamine from rat striatum measured by in vivo mudialysis
33. Selective increase in dopamine metabolism in the prefrontal cortex by the anxiogenic betacarboline FG7142
34. Modulation of mesoprefrontal dopamine neurons by central benzodiazepine receptors. 1 Pharmacological characterization
35. Selective activation of mesocortical dopaminergic system by stress
36. YM-09151-2 but not l-sulpiride induces transient dopamine release in rat striatum via a tetrodotoxin-insensitive mechanism
37. The use of tetrodotoxin for the characterization of drug-enhanced dopamine release in conscious rats studied by brain dialysis
38. A receptor subunit mRNAs in the rat brain. 1. Telecephalon, diencephalon, mesephalon
39. Actions of GABAergic agent on dopamine metabolism in the nigrostriatal pathway of the rat
40. 1 receptor mediation
41. Local administration of flurazepam has different effects on dopamine release in striatum and nucleus accumbens: a mudialysis study
42. Adenosine agonists can both inhibit and enhance in vivo striatal dopamine relese